BioLife Solutions, Inc. cash flow to debt ratio of 112.39% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

BioLife Solutions, Inc.'s free cash flow has increased 104.40% from $5.20M last year to $10.64M, signaling increasing performance

BioLife Solutions, Inc.'s debt to equity ratio is 0.04, which means that the company's assets are healthy financed, signaling financial stability.

BioLife Solutions, Inc.'s debt has decreased relative to shareholder equity from 0.09 last year to 0.04 today, signaling strengthened financials

BioLife Solutions, Inc. has a net cash position, so leverage is healthy.

BioLife Solutions, Inc.'s interest coverage ratio of 11.29 indicates that earnings with good margin can cover interest payments on company debt

BioLife Solutions, Inc.'s profit margin has increased (-299.94%) in the last year from -24.54% to 49.06%, signaling increasing performance

BioLife Solutions, Inc.'s short-term assets of $136.56M exceed its short-term liabilities of $22.98M

BioLife Solutions, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

BioLife Solutions, Inc.'s return on equity of 13.29%, is lower than 15.00%, indicating bad performance

BioLife Solutions, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

BioLife Solutions, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

BioLife Solutions, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

BioLife Solutions, Inc. has a free cash flow yield of 0.63%, which is below the 2.00% threshold, indicating limited cash return relative to market value

BioLife Solutions, Inc.'s yearly earnings has increased -39.90% since last year from $-20.18M to $-12.13M, signaling increasing performance

BioLife Solutions, Inc.'s yearly revenue has increased 16.97% since last year from $82.25M to $96.21M, signaling increasing performance

ROIC 1.71% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

BioLife Solutions, Inc.'s 3-year revenue CAGR of 8.07% is positive, indicating growing revenue over the past 3 years

BioLife Solutions, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

BioLife Solutions, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

BioLife Solutions, Inc. is overvalued relative to its fair value price of 4.23 based on Discounted Cash Flow model

BioLife Solutions, Inc. has an earnings yield of 2.98%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

BioLife Solutions, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

BioLife Solutions, Inc. has an EV/EBITDA ratio of 449.64x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

BioLife Solutions, Inc. is overvalued relative to its fair value price of -3.32 based on Earnings Fair Value model

BioLife Solutions, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioLife Solutions, Inc. has a price-to-book ratio of 4.03x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

BioLife Solutions, Inc. has a price-to-sales ratio of 16.46x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue